However, scrutinising the expression levels of these ECM components in short-term survivors of PDAC revealed a number of genes that were upregulated in these subjects and have been suggested to have a diagnostic, predictive, or prognostic value in different cancers, including S100A2 (pancreatic cancer), cathepsin H/CTSH (thyroid carcinoma), SERPINE1 (gastric cancer and oesophageal cancer), WNT7B (breast cancer and colorectal cancer), and GPC3 (hepatocellular carcinoma) [77,78,79,80,81,82,83,84]. This evidence concerns the gene S100A2 and breast cancer.